Sign inJoin waitlistJoin the waitlist

Christopher Hoimes

Instructor in the Department of Medicine · Duke Department of Medicine

Credentials: · · ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

Yale University
2006–2009
Penn State Milton S. Hershey Medical Center
2002–2005
New York Institute of Technology, College of Osteopathic Medicine
2001

Research

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
JAMA Oncology · 2017 · 722 citations
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Journal of Clinical Oncology · 2020 · 610 citations
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 496 citations

Petros Grivas
20 papers
Mehmet Bilen
19 papers
Ali Khaki
15 papers · 2 as a fellow
Yousef Zakharia
15 papers · 2 as a fellow
AA
Ajjai Alva
13 papers
AN
Ariel Nelson
13 papers
GS
Guru Sonpavde
13 papers
Matthew Milowsky
13 papers
Neeraj Agarwal
12 papers
Vadim Koshkin
12 papers
Shilpa Gupta
11 papers
Terence Friedlander
11 papers

Clinical trials

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Site PI · Recruiting · Phase 1, Phase 2
Novartis Pharmaceuticals
2025–2030